Debt-to-equity of Apellis Pharmaceuticals, Inc. from 30 Sep 2018 to 31 Dec 2025
- Taxonomy & unit
- ratio: x
- Description
- Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's debt by its shareholder equity.
- Summary
-
Apellis Pharmaceuticals, Inc. quarterly Debt-to-equity in x history and change rate from 30 Sep 2018 to 31 Dec 2025.
- Apellis Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 2.45x, a 3.5% decline year-over-year.
Debt-to-equity, Quarterly (x)
Debt-to-equity, YoY Quarterly Change (%)
Apellis Pharmaceuticals, Inc. Quarterly Debt-to-equity (x)
| Period | Value | YoY Chg | Change % | Date |
|---|---|---|---|---|
| Q4 2025 | 2.45x | -0.09x | -3.5% | 31 Dec 2025 |
| Q3 2025 | 2.76x | +0.2x | +7.8% | 30 Sep 2025 |
| Q2 2025 | 3.34x | +0.85x | +34% | 30 Jun 2025 |
| Q1 2025 | 2.91x | +0.68x | +31% | 31 Mar 2025 |
| Q4 2024 | 2.54x | +0.58x | +30% | 31 Dec 2024 |
| Q3 2024 | 2.56x | +0.57x | +28% | 30 Sep 2024 |
| Q2 2024 | 2.49x | +0.63x | +34% | 30 Jun 2024 |
| Q1 2024 | 2.23x | +0.28x | +14% | 31 Mar 2024 |
| Q4 2023 | 1.96x | -0.01x | -0.6% | 31 Dec 2023 |
| Q3 2023 | 1.99x | -0x | -0.06% | 30 Sep 2023 |
| Q2 2023 | 1.86x | -0.93x | -33% | 30 Jun 2023 |
| Q1 2023 | 1.95x | -4.09x | -68% | 31 Mar 2023 |
| Q4 2022 | 1.97x | -53.68x | -96% | 31 Dec 2022 |
| Q3 2022 | 2x | -49.21x | -96% | 30 Sep 2022 |
| Q2 2022 | 2.79x | -10.89x | -80% | 30 Jun 2022 |
| Q1 2022 | 6.04x | +1.3x | +27% | 31 Mar 2022 |
| Q4 2021 | 55.65x | +52.55x | +1694% | 31 Dec 2021 |
| Q3 2021 | 51.2x | +47.9x | +1450% | 30 Sep 2021 |
| Q2 2021 | 13.68x | +11.05x | +420% | 30 Jun 2021 |
| Q1 2021 | 4.74x | +2.59x | +121% | 31 Mar 2021 |
| Q4 2020 | 3.1x | +1.43x | +85% | 31 Dec 2020 |
| Q3 2020 | 3.3x | +2.4x | +264% | 30 Sep 2020 |
| Q2 2020 | 2.63x | +2.18x | +479% | 30 Jun 2020 |
| Q1 2020 | 2.14x | +1.88x | +703% | 31 Mar 2020 |
| Q4 2019 | 1.67x | +1.45x | +662% | 31 Dec 2019 |
| Q3 2019 | 0.91x | +0.7x | +332% | 30 Sep 2019 |
| Q2 2019 | 0.45x | 30 Jun 2019 | ||
| Q1 2019 | 0.27x | 31 Mar 2019 | ||
| Q4 2018 | 0.22x | 31 Dec 2018 | ||
| Q3 2018 | 0.21x | 30 Sep 2018 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.